Literature DB >> 31791236

Association of household secondhand smoke exposure and mortality risk in patients with heart failure.

Xin He1,2, Jingjing Zhao1,2, Jiangui He1,2, Yugang Dong3,4, Chen Liu5,6.   

Abstract

BACKGROUND: Secondhand smoke (SHS) exposure is a well-established cardiovascular risk factor, yet association between SHS and prognosis of heart failure remains uncertain.
METHOD: Data were obtained from the US National Health and Nutrition Examination Surveys III from 1988 to 1994. Currently nonsmoking adults with a self-reported history of heart failure were included. Household SHS exposure was assessed by questionnaire. Participants were followed up through December 31, 2011. Cox proportional-hazards models were used to assess the association of household SHS exposure and mortality risk. Potential confounding factors were adjusted.
RESULTS: Of 572 currently nonsmoking patients with heart failure, 88 were exposed to household SHS while 484 were not. There were totally 475 deaths during follow-up. In univariate analysis, household SHS was not associated with mortality risk (hazard ratio [HR]: 0.98, 95% confidence interval [CI]: 0.76-1.26, p = 0.864). However, after adjustment for demographic variables, socioeconomic variables and medication, heart failure patients in exposed group had a 43% increase of mortality risk compared with those in unexposed group (HR: 1.43, 95% CI: 1.10-1.86, p = 0.007). Analysis with further adjustment for general health status and comorbidities yielded similar result (HR: 1.47, 95% CI: 1.13-1.92, p = 0.005).
CONCLUSION: Household SHS exposure was associated with increased mortality risk in heart failure patients.

Entities:  

Keywords:  Heart failure; Mortality; Secondhand smoke

Mesh:

Substances:

Year:  2019        PMID: 31791236      PMCID: PMC6889209          DOI: 10.1186/s12872-019-1269-y

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


Background

Heart failure is a complex clinical syndrome with diverse etiology. It affects 1–2% adults and ≥ 10% elderly population in developed countries [1-4]. The lifetime risk of developing heart failure is so high as 20% for those older than 40 [5]. Prognosis of heart failure remains poor. Absolute mortality rate within 5 years is approximately 50% [6, 7]. Smoking is associated with higher risk of death in patients with left ventricular dysfunction, and therefore, smoking cessation is recommended in patients with heart failure [8-10]. Secondhand smoke (SHS) is another modifiable risk factor for cardiovascular diseases. Studies have shown that SHS also had significant adverse effect on cardiovascular system [11]. Although a previous study using cross-sectional data showed that SHS exposure was associated with lower quality of life in patients with heart failure [12], the effect of SHS exposure on prognosis of heart failure remains uncertain. Thus, we hypothesized that heart failure patients exposed to household SHS would have higher risk of all-cause mortality. We investigated the association of household SHS exposure and mortality risk using data of the US National Health and Nutrition Examination Surveys (NHANES) III.

Methods

Participants

NHANES III is cross-sectional survey in a nationwide probability sample of non-institutionalized civilian resident population in the United States. It is designed to assess the health and nutritional status of adults and children in the United States. From 1988 to 1994, 33,994 sample participants were interviewed and 30,818 participants were examined. Detailed descriptions of plan and operation of NHANES III is available on the website of National Center for Health Statistics [13]. The study was approved by the National Center for Health Statistics Research Ethics Review Board, and a signed informed consent form was obtained from every participant. Our study included currently nonsmoking adults (≥18 years) with a self-reported history of heart failure from survey participation. Participants with a history of non-skin cancer were excluded because of poor prognosis. There were totally 19,592 adults in NHANES III. Among them, 18,810 denied a history of heart failure, and 28 had no idea about their heart failure history. There were 757 participants with a history of heart failure in NHANES III. Among them, 126 current smokers and 59 participants with a history of non-skin cancer were excluded. Finally, 572 heart failure patients were included in the analysis.

Household SHS exposure

Data on household SHS exposure were obtained from the Family Characteristics section of the interview. The specific question was “Does anyone who lives here smoke cigarettes?” If the answer was yes, the participant was considered to be exposed to household SHS.

Outcome

Data on mortality status of included participants were obtained from the 2011 Public-Use Mortality Linked File. The file provided mortality follow-up data from the date of survey participation through December 31, 2011. Identifier data were matched to the National Death Index using a probabilistic matching algorithm. A detailed description of the linkage methodology has been published [14].

Statistical analysis

The primary analytic goal was to assess the association of household SHS exposure and mortality risk in patients with heart failure. Continuous variables were expressed as mean ± SD, and categorical variables were expressed as percentage. The differences between groups were tested by t test and Pearson’s chi-squared test, respectively. We calculated unadjusted rates of death per person-year. Kaplan-Meier survival curves and log-rank test were used to evaluate the mortality risk of SHS exposed and unexposed group. We used univariate Cox proportional-hazards models to assess the association of household SHS exposure and mortality risk. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. Follow-up began at the time of interview and ended on the date of death or December 31, 2011, whichever came first. We then used multivariate models to adjust for potential confounders. Model 1 included age, gender, race, education level, family income, urbanization classification of the county, medication, and NHANES III phase. Model 2 included variables in model 1, self-reported general health status, and comorbidities (hypertension, diabetes, hypercholesterolemia, myocardial infarction, chronic kidney disease, COPD/emphysema). Model 3 included variables in model 2, physical functioning, heart rate, systolic, and diastolic blood pressure. However, analysis of Model 3 was exploratory because physical functioning, blood pressure, and heart rate are probably in the causal pathway between SHS exposure and mortality among patients with heart failure. Subgroup analyses were performed among ex-smokers (those who had smoked at least 100 cigarettes) and never-smokers (those who hadn’t smoked 100 cigarettes). A sensitivity analysis was performed by excluding those who died within 6 months. We imputed missing values of covariates using multiple imputation with a Markov Chain Monte Carlo method. Variables listed in Table 1 were included in the imputation model. The assumption of proportional hazards was confirmed for all variables.
Table 1

Baseline characteristics of included participants

ExposedUnexposedp
n88484
Male, %47.347.70.943
Age, years66.1 + 17.170.8 + 12.60.001
Race, %0.003
 Non-Hispanic White37.549.4
 Non-Hispanic Black31.816.3
 Mexican-American25.031.2
 Other5.73.1
Region, %0.162
 Northeast12.512.4
 Midwest14.817.6
 South59.147.5
 West13.622.5
Urbanization Classificationa, %0.002
 155.761.8
 044.338.2
Education level, %0.759
 Education<12y65.567.2
 Education≥12y34.532.8
Economic Status, %
 Poverty income ratio < 264.568.20.509
 Poverty income ratio ≥ 235.531.8
 Family income< 20,000 dollars60.4730.019
 Family income≥20,000 dollars39.627
 Military service, %18.218.50.941
Household Size, %
 1 person0124 (25.6)< 0.001
 2 persons26 (29.6)223 (46.1)
  ≥ 3 persons62 (70.5)137 (28.3)
Medication, %
 ACEI17 (19.3)105 (21.7)0.617
 β-Blocker6 (6.82)79 (16.32)0.021
 Diuretic30 (34.1)216 (44.6)0.066
 Digitalis25 (29.4)144 (29.6)0.799
Ex-smoker, %51.046.60.443
Comorbidities, %
 Hypertensionb75.074.60.935
 Diabetesc33.035.10.694
 Hypercholesterolemiad71.670.30.819
 COPD/emphysemae22.730.20.157
 Chronic kidney diseasef71.576.80.309
 History of myocardial infarction39.852.20.033
Self-reported general health status, %0.535
 Poor31.227.9
 Good or fair68.872.1
Hospitalization during last year43.238.90.445
See doctors > 5 times during last year45.451.40.311

Physical functioning:

Difficulty in walking 10 steps without rest, %

0.148
 Yes62.753.5
 No37.346.5
Systolic blood pressure, mmHg142.2 + 24.1141.7 + 23.70.849
Diastolic blood pressure, mmHg77.3 + 14.373.8 + 13.50.028
Heart rate, bpm74.4 + 12.372.6 + 12.90.234
NHANES III phase, %0.314
 1988–199154 (61.4)269 (55.6)
 1991–199434 (38.6)215 (44.4)
Mean follow-up, years9.3 ± 7.19.2 ± 6.90.920

a1: Central or fringe counties of metro areas with a population of more than 1 million; 0: All other areas

bBP ≥140/90 mmHg or on antihypertensive medications or self-report

cHbA1c ≥ 6.5% or on diabetes medications or self-report

dTotal serum cholesterol ≥240 mg/dL or on anti-cholesterol medications or self-report

eForced expiratory volume 1/forced vital capacity ratio < 0.7 or self-report

fUrine albumin to urine creatinine ratio > 30 mg/g or estimated glomerular filtration rate < 60 mL/min/1.73m2

Baseline characteristics of included participants Physical functioning: Difficulty in walking 10 steps without rest, % a1: Central or fringe counties of metro areas with a population of more than 1 million; 0: All other areas bBP ≥140/90 mmHg or on antihypertensive medications or self-report cHbA1c ≥ 6.5% or on diabetes medications or self-report dTotal serum cholesterol ≥240 mg/dL or on anti-cholesterol medications or self-report eForced expiratory volume 1/forced vital capacity ratio < 0.7 or self-report fUrine albumin to urine creatinine ratio > 30 mg/g or estimated glomerular filtration rate < 60 mL/min/1.73m2 All P values are two-tailed, and estimates with P values of less than 0.05 were considered statistically significant. All analyses were performed using STATA 13.

Results

Baseline characteristics

Baseline characteristics were summarized in Table 1. Eighty-eight patients were exposed to household SHS, and 484 were not. Exposed patients were younger than the unexposed. Patients with household SHS exposure were more likely to be non-Hispanic Black, have a family income of more than 20,000 dollars, and have a larger household size, while those without exposure were more likely to live in an urbanized area, take beta-blockers, and have a history of myocardial infarction. The mean diastolic blood pressure in exposed group was 3.5 mmHg higher than that in unexposed group. Other baseline characteristics were comparable in both groups.

All-cause mortality

During a mean follow-up period of 9.2 years, there were 475 deaths (72 deaths in exposed group and 403 deaths in unexposed group). Rates of death per person-year were comparable between two groups (88.0 and 90.4 deaths per 1000 person-years in exposed group and unexposed group, respectively) (Table 2). Kaplan-Meier survival curves showed similar results (P for log-rank test = 0.864) (Fig. 1). Results of Cox regression models were summarized in Table 3. In the univariate analysis, household SHS exposure was not associated an increased mortality risk (HR: 0.98, 95% CI: 0.76–1.26, p = 0.854). However, after adjusting for demographic variables, socioeconomic variables, and medication in Model 1, household SHS exposure was associated of a 43% increase of mortality risk (HR: 1.43, 95% CI: 1.10–1.86, p = 0.007). Model 2 further adjusted for self-reported general health status and baseline comorbidities, and HR for the association was 1.47 (95% CI: 1.13–1.92, p = 0.005). Result in Model 3 was consistent. In subgroup analyses, the associations of household SHS and mortality risk did not differ significantly between ex-smokers and never-smokers (p for interaction> 0.1). Excluding death within 6 months did not significantly change the results (HR: 1.38, 95% CI: 1.05–1.82, p = 0.020 for Model 1; HR: 1.42, 95% CI: 1.08–1.88, p = 0.014 for Model 2; HR: 1.35, 95% CI: 1.02–1.80, p = 0.037).
Table 2

Mortality incidence rate in household secondhand smoke exposed and unexposed group

Number of mortalityPerson-yearIncidence rate, per 1000 person-year
Exposed72817.888.0
Unexposed4034,48.890.4
Fig. 1

Kaplan-Meier survival curves of household secondhand smoke exposed and unexposed

group.

Table 3

Associations of household SHS exposure and mortality risk among currently nonsmoking patients with heart failure

Univariate ModelModel 1Model 2Model 3
HR95% CIpp for interactionHR95% CIpp for interactionHR95% CIpp for interactionHR95% CIpp for interaction
Overall0.980.76–1.260.8641.431.10–1.860.0071.471.13–1.920.0051.401.07–1.840.016
Never-smoker1.020.72–1.460.8890.3071.410.96–2.080.0790.6391.511.02–2.230.0400.9211.390.93–2.090.1120.620
Ex-smoker0.960.67–1.370.8291.481.02–2.170.0401.460.98–2.180.0661.470.98–2.220.065

HR hazard ratio, CI confidence interval

Model 1 adjusted for age, gender, race, education level, family income, urbanization classification, and medications, NHANES III phase

Model 2 adjusted for variables in Model 1, general health status, and comorbidities

Model 3 adjusted for variables in Model 2 and physical functioning, heart rate, systolic, and diastolic blood pressure

Mortality incidence rate in household secondhand smoke exposed and unexposed group Kaplan-Meier survival curves of household secondhand smoke exposed and unexposed group. Associations of household SHS exposure and mortality risk among currently nonsmoking patients with heart failure HR hazard ratio, CI confidence interval Model 1 adjusted for age, gender, race, education level, family income, urbanization classification, and medications, NHANES III phase Model 2 adjusted for variables in Model 1, general health status, and comorbidities Model 3 adjusted for variables in Model 2 and physical functioning, heart rate, systolic, and diastolic blood pressure

Discussion

This study suggested that household SHS exposure was associated with an increased risk of death among heart failure patients. The results were consistent in analyses with different levels of adjustment. As far as we know, this is the first study to assess the association between household SHS exposure and mortality risk of heart failure. Suskin et al. analyzed data from the Studies of Left Ventricular Dysfunction trials, and found that active smoking was associated with a 41% increase of mortality risk among patients with left ventricular dysfunction. This study also found no significant difference in mortality risks between ex-smokers and never-smokers, suggesting that smoking cessation could reduce the mortality risk [9]. In our analyses among currently nonsmoking adults, HRs for associations of household SHS exposure and mortality risk ranged from 1.40 to 1.47 with different levels of adjustment. In the subgroup analyses, associations of household SHS and mortality risk were similar among ex-smokers and never-smokers. These results implied that effect of household SHS on mortality risk could be as large as active smoking, and that exposure to household SHS could eliminate the benefit of smoking cessation among patients with heart failure. The substantial effect of household SHS on heart failure prognosis makes it an unignorable risk factor. More attention should be paid on avoiding exposure of household SHS in management of heart failure. Personal smoking cessation will be in vain if a smoke-free environment is not provided. Unlike multivariate analyses, univariate analyses did not found any significant associations. This could be explained by differences of baseline characteristics, especially age. Among the heart failure patients included in our analyses, those exposed to household SHS were significantly younger, probably reflecting shorter life spans of patients in this group. Harmful effect of household SHS could be covered by survival advantage of younger age. Besides, relatively high family income might also contribute to the differences between univariate and multivariate analyses [15]. The mechanisms of this detrimental effect are still not clear, but there are several possible explanations. Studies have shown that both acute and chronic SHS exposure are associated with decreased heart rate variability, which indicates a shift in the sympathovagal balance toward sympathetic predominance [16-18]. Sustained activation of sympathetic nervous system exerts deleterious effects on cardiovascular system in heart failure patients [19]. SHS exposure also leads to increased inflammation and oxidative stress, which are important in the progression of heart failure [11, 20, 21]. Our study has several limitations. First, history of heart failure was obtained from answer to questionnaire instead of medical record, which could introduce significant recall bias. Second, we lacked information about etiology of heart failure, New York Heart Association class, and ejection fraction, and could not include them in the multivariate analysis. These are important factors that affect the prognosis of heart failure. Third, only a very low proportion of patients in this study took medication for heart failure. Therefore, results of this study needed to be verified in current standard heart failure cohort. Fourth, we did not assess SHS exposure in the workplace, public places, social situations, etc. SHS exposure outside of the household could bias the results. Fifth, the sample size was limited. There were only 88 participants in the exposed group, which might explain the non-significant results in subgroup analyses. Given the limitations mentioned above, results of this study should be interpreted with caution. Sixth, reverse causality could not be ruled out in this study. As family member might pay more attention to patient care if heart failure was more severe. Therefore, advanced heart failure patients might be less likely exposed to household SHS, and the effect of SHS in this study might be underestimated. Seventh, SHS was not included as a time-dependent variable. As SHS exposure status could change during follow-up, using baseline SHS could introduce bias. Eighth, our study assessed SHS only as a binary variable. The dose-response relation of SHS and prognosis of heart failure should be evaluated in detail in future study. Nevertheless, there were also several strengths in this study. First, using data from a nation-wide survey, the studied participants were representative of heart failure patients in community. Second, current smokers were not included in this study to avoid the influence of active smoking. Although former smokers were included, the effect of former smoking was also evaluated in a subgroup analysis. Third, average follow-up period was almost 10 years in this study, which was long enough to assess the long-term effect of SHS.

Conclusions

In conclusion, household SHS exposure was associated with increased mortality risk in currently nonsmoking patients with heart failure, which was similar in magnitude to the effect of active smoking. The detrimental effect of household SHS exposure was consistent among ex-smokers never-smokers. Avoidance of household SHS should be a crucial part of management of heart failure.
  19 in total

1.  Secondhand smoke exposure and quality of life in patients with heart failure.

Authors:  Sarah G Weeks; Stanton A Glantz; Teresa De Marco; Alisa B Rosen; Kirsten E Fleischmann
Journal:  Arch Intern Med       Date:  2011-11-28

Review 2.  Cardiovascular effects of secondhand smoke: nearly as large as smoking.

Authors:  Joaquin Barnoya; Stanton A Glantz
Journal:  Circulation       Date:  2005-05-24       Impact factor: 29.690

3.  Effects of passive smoking on heart rate variability, heart rate and blood pressure: an observational study.

Authors:  Denise Felber Dietrich; Joel Schwartz; Christian Schindler; Jean-Michel Gaspoz; Jean-Claude Barthélémy; Jean-Marie Tschopp; Frédéric Roche; Arnold von Eckardstein; Otto Brändli; Philippe Leuenberger; Diane R Gold; Ursula Ackermann-Liebrich
Journal:  Int J Epidemiol       Date:  2007-04-17       Impact factor: 7.196

4.  Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes.

Authors:  Amanda K Verma; Phillip J Schulte; Vera Bittner; Steven J Keteyian; Jerome L Fleg; Ileana L Piña; Ann M Swank; Meredith Fitz-Gerald; Stephen J Ellis; William E Kraus; David J Whellan; Christopher M O'Connor; Robert J Mentz
Journal:  Am Heart J       Date:  2016-10-15       Impact factor: 4.749

5.  Long-term trends in the incidence of and survival with heart failure.

Authors:  Daniel Levy; Satish Kenchaiah; Martin G Larson; Emelia J Benjamin; Michelle J Kupka; Kalon K L Ho; Joanne M Murabito; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

6.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

7.  Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study.

Authors:  Gysèle S Bleumink; Anneke M Knetsch; Miriam C J M Sturkenboom; Sabine M J M Straus; Albert Hofman; Jaap W Deckers; Jacqueline C M Witteman; Bruno H Ch Stricker
Journal:  Eur Heart J       Date:  2004-09       Impact factor: 29.983

8.  Trends in heart failure incidence and survival in a community-based population.

Authors:  Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

9.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Acute exposure to environmental tobacco smoke and heart rate variability.

Authors:  C A Pope; D J Eatough; D R Gold; Y Pang; K R Nielsen; P Nath; R L Verrier; R E Kanner
Journal:  Environ Health Perspect       Date:  2001-07       Impact factor: 9.031

View more
  1 in total

1.  Angina Outcomes in Secondhand Smokers: Results from the National Health and Nutrition Examination Survey 2007-2018.

Authors:  Suzanne Chaar; Jeik Yoon; Joud Abdulkarim; José Villalobos; Jeanette Garcia; Humberto López Castillo
Journal:  Avicenna J Med       Date:  2022-07-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.